Ocugen (OCGN) Other financing activities (2014 - 2026)

Ocugen (OCGN) posted Other financing activities of $15.0 million for Q1 2026, up 2387.56% on a QoQ basis from $603000.0 in Q2 2021.

Ocugen (OCGN) Other financing activities (2014 - 2026) Analysis & Trends

Ocugen's Other financing activities history runs 9 years deep, the most recent figure standing at $15.0 million for Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (changed N/A YoY) and the FY2021 annual result came in at $603000.0, changed N/A from the prior year.
Other financing activities was $15.0 million for Q1 2026 at Ocugen, up from $603000.0 in the prior quarter.
Across five years, Other financing activities topped out at $15.0 million in Q1 2026 and bottomed at $15.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ocugen	63.79 Mn	63.79 Mn	-

Download Data